By Elaine Rigoli
Tampa, Fla., May 22 - U3 Pharma AG has raised €27 million in a third private equity financing round led by Life Sciences Partners.
Existing investors, including Alta Partners, Atlas Venture, E. de Rothschild Investment Partners and Bio*One Capital, also participated in the oversubscribed round.
The funding will accelerate the further development of the company's pipeline of antibody-based targeted cancer therapeutics, according to a news release.
Located in Martinsried, Germany, U3 Pharma is a translational medicine-focused oncology company.
| Issuer: | U3 Pharma AG
|
| Issue: | Private equity financing, third round
|
| Amount: | €27 million
|
| Investors: | Life Sciences Partners, Alta Partners, Atlas Venture, E. de Rothschild Investment Partners and Bio*One Capital
|
| Announcement date: | May 22
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
